Dengzhan Shengmai capsules and their active component scutellarin prevent cognitive decline in APP/PS1 mice by accelerating A β aggregation and reducing oligomers formation.

In conclusion, DZSM capsules protected against cognitive defects of AD through scutellarin-mediated acceleration of Aβ aggregation into fibrils or protofibrils and reduction of soluble Aβ oligomers, thus suggesting potential clinical applications of DZSM capsules and scutellarin in the treatment of AD. PMID: 31810113 [PubMed - in process]

https://www.ncbi.nlm.nih.gov/pubmed/31810113?dopt=Abstract

Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - December 9, 2019 Category: Drugs & Pharmacology Authors: Zhang S, Zhang J, Wei D, An H, Liu W, Lai Y, Yang T, Shao W, Huang Y, Wang L, Dou F, Peng D, Zhang Z Tags: Biomed Pharmacother Source Type: research